Pre-Made Darbepoetin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting EPOR for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Darbepoetin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting EPOR is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Darbepoetin alfa (INN) /d¨»?rb??po??t?n/ is a re-engineered form of erythropoietin containing 5 amino acid changes (N3, T32, V87, N88, T9) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Darbepoetin is marketed by Amgen under the trade name Aranesp.
Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
| Products Name (INN Index) | Pre-Made Darbepoetin Alfa biosimilar, Recombinant Protein: Recombinant therapeutic protein targeting EPOR |
|---|---|
| INN Name | darbepoetin alfa |
| Target | EPOR |
| Format | Recombinant Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | EPO |
| VD LC | EPO |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Amgen (Thousand Oaks CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EPOR |
| Package |
